Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial-Reference-Cited by-同舟云学术

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

Published:2018-06 Issue:10139 Volume:391 Page:2503-2512
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Burmester Gerd R,Kremer Joel M,Van den Bosch Filip,Kivitz Alan,Bessette Louis,Li Yihan,Zhou Yijie,Othman Ahmed A,Pangan Aileen L,Camp Heidi S

Publisher

Elsevier BV

Subject

General Medicine

Reference28 articles.

1. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force;Smolen;Ann Rheum Dis,2016

2. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial;van der Heijde;J Rheumatol,2012

3. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients;Aletaha;Arthritis Rheum,2007

4. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis;Singh;Arthritis Rheumatol,2016

5. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update;Smolen;Ann Rheum Dis,2017

Cited by 316 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JAK inhibitor selectivity: new opportunities, better drugs?;Nature Reviews Rheumatology;2024-09-09

2. Real-world study comparing the efficacy of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis;Clinical Rheumatology;2024-09-07

3. Clinical and Ultrasonographic Remission in Bio-naïve and Bio-failure Patients with Rheumatoid Arthritis at 24 Weeks of Upadacitinib Treatment: The UPARAREMUS Real-Life Study;Rheumatology and Therapy;2024-08-23

4. Oncostatin M-driven macrophage-fibroblast circuits as a drug target in autoimmune arthritis;Inflammation and Regeneration;2024-07-31

5. Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis;PLOS ONE;2024-07-31